Beyond Air, Inc. (XAIR)

US stock futures higher. Chagee Holdings, Tilray Brands, Globus Maritime, Post Holdings, and Beyond Air in focus.

GARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Doug Larson has resigned as Chief Financial Officer to pursue another opportunity.

Beyond Air, Inc. ( XAIR ) Q2 2026 Earnings Call November 10, 2025 4:30 PM EST Company Participants Steven Lisi - CEO & Chairman of the Board Douglas Larson - Chief Financial Officer Conference Call Participants Garth Russell - Lifesci Advisors, LLC Justin Walsh - JonesTrading Institutional Services, LLC, Research Division Yale Jen - Laidlaw & Company (UK) Ltd., Research Division Sam Eiber - BTIG, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Beyond Air financial results call for the fiscal quarter ended September 30, 2025.

Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025 Achieves certificate for Medical Device Single Audit Program (MDSAP) Updated fiscal year 2026 revenue guidance to $8 – $10 million Conference call at 4:30 p.m. ET today, November 10 th GARDEN CITY, N.Y.

GARDEN CITY, N.Y., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Douglas Larson, Chief Financial Officer of Beyond Air, will participate in the ROTH 4th Annual Healthcare Opportunities Conference, which is being held on Thursday, October 9, 2025, in New York, NY.

GARDEN CITY, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding common warrants (the “Existing Warrants”) to purchase up to an aggregate of 1,439,126 shares of the Company's common stock at a reduced exercise price of $2.21 (the closing price of the Company's shares of common stock on September 5, 2025). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $3.25 million, prior to deducting placement agent fees and estimated offering expenses.

GARDEN CITY, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.

These recent LungFit PH international agreements bring the ex-U.S. total to 34 countries and a combined population of 2.7 billion people These recent LungFit PH international agreements bring the ex-U.S. total to 34 countries and a combined population of 2.7 billion people

Beyond Air, Inc. (NASDAQ:XAIR ) Q1 2026 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Douglas Quinton Larson - Chief Financial Officer Steven Adam Lisi - CEO & Chairman of the Board Conference Call Participants I-Eh Jen - Laidlaw & Company (UK) Ltd., Research Division Jason Hart Wittes - ROTH Capital Partners, LLC, Research Division Jason M.

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.5. This compares to a loss of $5.4 per share a year ago.

GARDEN CITY, N.Y., July 25, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its first fiscal quarter ended June 30, 2025 on Tuesday, August 12, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.

GARDEN CITY, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, has been awarded a national group purchasing agreement for therapeutic gases with Premier, Inc. Effective July 15th, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the LungFit PH system and disposable NO2 Smart Filters.

After losing some value lately, a hammer chart pattern has been formed for Beyond Air (XAIR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Medical Opinion Concludes that Beyond Oil has Potential to Reduce Gastrointestinal Cancer Risk Among Consumers of Fried Foods and Food Service Workers Medical Opinion Concludes that Beyond Oil has Potential to Reduce Gastrointestinal Cancer Risk Among Consumers of Fried Foods and Food Service Workers

Beyond Air, Inc. (NASDAQ:XAIR ) Q4 2025 Earnings Conference Call June 17, 2025 4:30 PM ET Company Participants Douglas Quinton Larson - CFO, Principal Financial Officer & Principal Accounting Officer Steven Adam Lisi - CEO & Chairman of the Board Conference Call Participants I-Eh Jen - Laidlaw & Company (UK) Ltd., Research Division Jason Hart Wittes - ROTH Capital Partners, LLC, Research Division Joseph Daniel Downing - Piper Sandler & Co., Research Division Justin Howard Walsh - JonesTrading Institutional Services, LLC, Research Division Marie Yoko Thibault - BTIG, LLC, Research Division Corey George Davis - Lifesci Advisors, LLC Operator Good afternoon, and welcome, everyone, to the Beyond Air Financial Results Call for the Fiscal Quarter and Year Ended March 31, 2025.